Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN (NYSE: QGEN) appointed Jonathan M. Pratt as Chief Executive Officer, effective September 1, 2026, succeeding Thierry Bernard. Pratt brings more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare, most recently as President and CEO of Filtration Group, which he led through its sale to Parker-Hannifin in August 2026.
According to QIAGEN, the Supervisory Board chose Pratt after a comprehensive search, citing his global industry knowledge and record of improving performance in analytical instruments, laboratory technologies and bioprocessing. He will also be proposed as a Managing Director at an Extraordinary General Meeting planned for the fourth quarter of 2026. Bernard will support an orderly transition through year-end.
QIAGEN reaffirmed its outlook for the third quarter and full-year 2026 and stated that its strategic review, supported by independent financial and legal advisors, remains ongoing. The company continues to target solid profitable growth and disciplined capital allocation.
QIAGEN (NYSE: QGEN) announced U.S. FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, its first QIAstat-Dx panel for bloodstream infections. The test detects 20 gram-positive bacterial and fungal pathogen targets, a broad pan gram-negative target and 10 genetic antimicrobial resistance markers from positive blood cultures in about one hour.
The clearance marks QIAGEN’s entry into U.S. bloodstream infection testing and adds a fourth major infectious disease area to the QIAstat-Dx syndromic platform, which is available in more than 100 countries with over 5,200 cumulative placements as of end-2025. QIAGEN is also pursuing FDA review of a complementary QIAstat-Dx BCID GN Plus AMR Panel focused on gram-negative pathogens.
QIAGEN (NYSE: QGEN) reported Q2 2026 net sales of $535 million, unchanged from Q2 2025 on a reported and constant exchange rate (CER) basis, but ahead of an outlook for about a 2% CER decline. Growth pillars delivered about 5% CER sales growth, led by Sample technologies, QIAcuity and QIAGEN Digital Insights, while QuantiFERON rose 1% CER and QIAstat-Dx faced a tough comparison in respiratory testing.
The adjusted operating income margin was 29.4%, with diluted EPS of $0.50 and adjusted diluted EPS of $0.62, above the outlook for at least $0.60 CER. Operating cash flow reached $301 million in H1 2026, and QIAGEN reaffirmed its full-year 2026 outlook for net sales growth of about 1–2% CER and adjusted diluted EPS of at least $2.43 CER. The company also highlighted a 40% dividend increase versus 2025 and ongoing investments following the Parse acquisition.
QIAGEN (NYSE: QGEN) is highlighting its molecular testing portfolio as U.S. cyclosporiasis cases climb above 1,600 confirmed since May 2026, with another 7,000 potential cases under investigation. Health authorities are tracking multiple outbreaks of Cyclospora cayetanensis, a foodborne parasite not detectable by routine stool culture.
According to QIAGEN, its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 detects Cyclospora within about an hour as part of a 16-target gastrointestinal menu. For research and public health applications, QIAGEN offers a Cyclospora digital PCR assay for the QIAcuity system and the PulseNet-approved QIAseq FX DNA Library Prep Kit to support shotgun NGS workflows for identifying and characterizing foodborne pathogens.
QIAGEN (NYSE: QGEN) will release its Q2 2026 results on Wednesday, August 5, 2026, shortly after 22:05 Frankfurt / 21:05 London / 16:05 New York time. A related conference call will be held on Thursday, August 6, 2026, at 15:30 Frankfurt / 14:30 London / 09:30 New York time, with options to join by call-back registration, phone dial-in, or live audio webcast.
QIAGEN (NYSE: QGEN) has launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, expanding its QIAstat-Dx bloodstream infection testing menu. The new gram-negative panel detects 13 bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour.
Together with the recently introduced BCID GPF Plus AMR Panel, QIAstat-Dx now covers 33 pathogen targets and 28 AMR markers across gram-positive and gram-negative bacteria and fungi. The system is deployed in over 100 countries with more than 5,200 instruments installed as of end 2025.
QIAGEN (NYSE:QGEN) announced expansions to its QIAcuity digital PCR ecosystem to support wider adoption in research and biopharma. New offerings include planned gene expression assays for human, mouse and rat, a high-multiplex RNA kit, expanded Cell and Gene Therapy quality-control assays, enhanced QIAcuity Software 3.5 and Hamilton-based automation.
According to QIAGEN, QIAcuity has over 3,200 placements worldwide, 400+ multi-instrument customers and 1,100+ publications.
QIAGEN (NYSE:QGEN) announced two custom research-use-only QIAcuity digital PCR assays targeting Bundibugyo ebolavirus sequences linked to the current outbreak. These assays, designed for the QIAcuity system, focus on the virus’s NP and VP35 regions to support research, wastewater surveillance and environmental monitoring.
Initial in silico analysis showed no mismatches with reviewed outbreak sequences. The assays are make-to-order via QIAGEN’s custom workflow and complement in-stock QIAseq sequencing panels and sample preparation kits within the broader Sample to Insight portfolio.
QIAGEN (NYSE:QGEN) launched QIA Agent, an AI-powered digital assistant that supports experiment planning, product discovery and workflow guidance through a single conversational interface on www.qiagen.com.
The platform links natural-language queries to QIAGEN products, protocols, technical documentation and ordering tools, leveraging over 260,000 registered My QIAGEN users. It is globally available for research use only, not for diagnostic applications.
QIAGEN (NYSE:QGEN) is integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform into QIAGEN Digital Insights’ curated biomedical knowledge bases to support AI-driven drug discovery.
The collaboration applies graph-based AI to biomedical knowledge graphs to aid target identification, biomarker discovery and hypothesis generation, with initial pilot programs for select pharma and biotech partners.